DEEP:CHEST to be installed on SG Healthcare’s export X-ray systems and exported to Uzbekistan’s medical market
SG Healthcare strengthens its global market strategy by combining its products with DEEPNOID’s AI technology
The two companies will combine their capabilities to deliver an integrated end-to-end solution, creating synergies that strengthen the competitiveness of Korea’s medical industry
DEEPNOID, one of Korea’s first-generation medical AI companies (CEO Woo Sik Choi), is entering the global medical AI market through a strategic partnership with SG Healthcare (CEO Jeong Su Kim), a company specializing in diagnostic imaging devices.
DEEPNOID recently signed a supply agreement with SG Healthcare for DEEP:CHEST, its real-time detection and diagnosis-assistance solution for multiple lung diseases. The agreement covers a total of 68 units, delivered on-premises. DEEP:CHEST will be installed on X-ray systems that SG Healthcare supplies to Uzbekistan and other overseas markets. With this agreement, the two companies plan to build a strategic partnership in the global medical market.
By combining SG Healthcare’s hardware and image quality enhancement AI with DEEPNOID’s interpretation AI and report generation AI, the two companies can deliver a vertically integrated, end-to-end package covering image acquisition, preprocessing, interpretation, and radiology report generation. Going forward, they plan to gradually expand their strategic collaboration, including developing integrated hardware-software packages and jointly entering overseas projects.
SG Healthcare is the only diagnostic imaging device company in Korea with a full lineup of products. It supplies its products through 136 distribution channels in 81 countries worldwide, raising the profile of Korean medical devices. In AI software, the company has secured world-class AI noise cancellation technology, allowing it to respond proactively to changing market needs. Through this strategic partnership with DEEPNOID, the two companies plan to combine their distinctive technological strengths to further strengthen their position in the global market.
“Our collaboration with DEEPNOID is an important first step toward increasing global competitiveness by combining the strengths of Korean medical devices and AI technology,” said Jeong Su Kim, CEO of SG Healthcare. “We will continue to strengthen the international standing of Korean medical AI technology through a variety of partnerships.”
“I see this partnership not just as a supply agreement but as a starting point for increasing the global competitiveness of Korean medical devices,” said Woo Sik Choi, CEO of DEEPNOID. “I am confident that combining SG Healthcare’s hardware technology with DEEPNOID’s AI interpretation software capabilities will bring new value to healthcare settings around the world.”
###
